Abstract
Two glioma driver mutations in PIK3CA promote neuronal hyperactivity via distinct mechanisms.
Major Finding: Two glioma driver mutations in PIK3CA promote neuronal hyperactivity via distinct mechanisms.
Concept: One mutant had cell-autonomous effects; the other did not and depended on glypican 3 function.
Impact: This work identified two PIK3CA driver mutations and characterized mechanisms of gliomagenesis.
Based on the fact that the RTK–RAS–PI3K pathway is dysfunctional in 90% of glioblastomas, Yu, Lin, and colleagues used a native mouse model of glioblastoma to perform high-throughput in vivo screening for PIC3KA mutations that drive glioma formation. This screen identified previously known hotspot mutations as well as new potential driver mutations, each of which accelerated glioma formation to a different extent. Further, as RNA-sequencing (RNA-seq) experiments revealed, the variants may even have promoted glioma formation via distinct molecular mechanisms. Serial video electroencephalography experiments showed that the presence of either of two putative driver mutations in PIC3KA identified in the screen (C420R and H1047R) in tumors promoted network hyperexcitability at early stages of tumor progression. Examination of the tumor microenvironments (TME) of PIC3KAC420R- and PIC3KAH1047R-driven tumors revealed that there were more excitatory synapses and fewer inhibitory synapses at the peritumoral margins than in the TME of tumors driven by a PIC3KA mutation not associated with hyperexcitability. The findings regarding hyperexcitability and synaptic alterations in the TME were confirmed using patient-derived xenograft models in which mice were transplanted with glioma stem-cell lines overexpressing each PIC3KA variant. Despite the aforementioned similarities between PIC3KAC420R- and PIC3KAH1047R-driven tumors, further experiments revealed that the H1047R mutation induced neuronal hyperexcitability on its own in a nontumor context, whereas the C420R mutation did so only in glial tumors, implying differences in the underlying mechanisms. Deeper analysis of the RNA-seq data suggested that glypican 3 (GPC3) contributed to the non–cell autonomous mechanism by which the C420R mutation promoted tumorigenesis and the observed synaptic abnormalities. Indeed, mice bearing Gpc3-knockout tumors harboring PIC3KAC420R had extended survival compared with PIC3KAC420R-mutant tumors with wild-type Gpc3, and tumors overexpressing Gpc3 exhibited earlier-onset neuronal hyperexcitability and caused convulsive seizures at earlier stages. Combined with recent findings that increased neuronal activity promotes glioma proliferation, these results support the role of a positive feedback mechanism wherein gliomas induce neuronal hyperactivity and that hyperactivity promotes glioma growth.
Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.